Seroprevalence of poliovirus antibodies in Nigeria: refining strategies to sustain the eradication effort

• Published in: The Pan African medical journal 2023, Vol.45 (Suppl 2), p.2-2
• Main Authors: Bolu, Omotayo, Adamu, Usman, Franka, Richard, Umeokonkwo, Chukwuma David, An, Qian, Greby, Stacie, McDonald, Sharla, Mainou, Bernardo, Mba, Nwando, Agala, Ndidi, Archer, Wiedad Roodly, Braka, Fiona, Etapelong, Sume Gerald, Gashu, Tegegne Sisay, Siddique, Anisur Rahman, Asekun, Adeyelu, Okoye, McPaul, Iriemenam, Nnaemeka, Wiesen, Eric, Swaminathan, Mahesh, Ihekweazu, Chikwe, Shuaib, Faisal
• Format: Article
• Language: English
• ISSN: 1937-8688; 1937-8688
• DOI: 10.11604/pamj.supp.2023.45.2.38098

in 2016, a switch from trivalent oral poliovirus vaccine (OPV) (containing serotypes 1,2,3) to bivalent OPV (types 1,3) was implemented globally. We assessed the seroprevalence of poliovirus antibody levels in selected Nigerian states, before and after the switch, documented poliovirus type2 outbreak responses conducted and ascertained factors associated with immunity gaps based on seroprevalence rates. we conducted a secondary analysis of stored serum samples from the 2018 Nigeria National HIV/AIDS Indicator and Impact Survey. Serum from 1,185 children aged 0-119 months residing in one southern and four northern states were tested for serotype-specific PV neutralizing antibodies; seropositivity was a reciprocal titer ≥8. We conducted regression analysis to determine sociodemographic risk factors associated with low seroprevalence using SAS 9.4. children aged 24-119 months (pre-switch cohort) had seroprevalence against PV1, PV2, and PV3, of 97.3% (95% CI:96.4-98.2), 93.8% (95% CI:92.2-95.5), and 91.3% (95% CI:89.2-93.4), while children aged